CRDL Stock Cardiol Therapeutics Inc.
US · NasdaqCMLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Cardiovascular pipeline catalysts and unanimous bullish coverage create high-risk upside.
Signal breakdown
- ▸Consensus Strong Buy with a $10 average price target.
- ▾Below 50-day MA (-36.53%)
Is CRDL a buy right now?
Trend: CRDL is trading below the 50-day average (-33.73%), RSI 50 — neutral momentum, with a 3-month return of -3.03%.
Valuation & quality: Cardiol Therapeutics Inc. trades on forward P/E -4.8, price-to-book 7.60; fundamentals show net margin 0.0%, return on equity -190.2%.
Analyst consensus: 5 analysts have a mean 12-month price target of $8.58 (+666.1% vs the last close; range $5.05 – $11.20), consensus rating “strong buy”.
Our screen: BUY (score 2) — Cardiovascular pipeline catalysts and unanimous bullish coverage create high-risk upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +32.40% | +2.20% | -11.60% | -13.10% | +19.80% | +55.90% | -16.20% | -32.50% |
Fundamentals
Analyst price target
Technical signals
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · Canada · 18 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.